New Neuronal IDOL Target Could Cut Alzheimer's Plaque Burden

Researchers at Indiana University identified neuronal IDOL as a new drug target for Alzheimer’s, showing that reducing IDOL activity in brain neurons lowers amyloid plaques and APOE levels, while boosting receptors that regulate APOE and amyloid. The neuron-focused approach produced stronger effects than targeting microglia, suggesting a potential multi-benefit therapy. Next steps include preclinical safety testing and evaluating whether IDOL blockade preserves synapses and reduces tau pathology.